Innate Pharma reports 2010 financial results and updates on its drug candidates

• Strong balance sheet and controlled cash burn
  
• Two drug candidates in clinical trials, one of which licensed to Novo Nordisk A/S
  
• Six clinical trials in the US and Europe for IPH 21 program

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) reports today its consolidated financial results for the year ending December 31, 2010. Unaudited consolidated financial statements are attached to this press release.